Secondary prostate cancer
The hormone-sensitive cells die and the hormone-resistant cells overgrow, resulting in disease progression. The drug of choice for secondary treatment is estramustine Estracyt.
Bone Metastasis: Treatments, Scans \u0026 Side Effects - Ask a Prostate Expert, Mark Scholz, MD
The success of secondary prostate cancer therapy is followed by changes of the prostate-specific antigen level and Karnofsky scale. In the present study, the results of estramustine treatment of 79 patients with advanced prostate cancer in 12 hospitals were evaluated.
The mean prostate-specific antigen level improved for 6 months, but rose from the ninth month on. The improvement in the subjective condition of the patients paralleled the change in the prostate-specific antigen level.
The short time of improvement was a consequence of the very high prostate-specific antigen level and the poor general condition.
Subjects must meet all of the following criteria to be enrolled in this study: 1. Male aged 21 years or older. Ability to provide signed informed consent and willingness to comply with protocol requirements. Biopsy confirmed presence of adenocarcinoma of the prostate gland. At high-risk for metastatic disease by a stage of cT3, cT4, or a total nomogram score of greater than or equal to 5.
Estramustine administration is recommended when the prostate-specific antigen level becomes more than doubled following primary treatment. If the prostate-specific antigen level has not decreased after treatment for 3 months, the secondary strategy is to apply chemotherapy. Publication types.